Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma Interventions: Biological: Obinutuzumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Venetoclax Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Research | Study